Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Fischer A, Zimovetz E, Ling C, Esser D, Shoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017 Nov;16(11):1147-54. doi: 10.1016/j.autrev.2017.09.010
Purroy F, Cruz Esteve I, Galindo Ortego MG, Marsal Mora JR, Oro M, Plana A. Survey of the knowledge and management of transient ischemic attacks among primary care physicians and nurses. Neurologia. 2011 May;26(4):200-7. doi: 10.1016/j.nrl.2010.04.011
Küçükdeveci AA, McKenna SP, Kutlay S, Gürsel Y, Whalley D, Arasýl T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res. 2000 Mar 1;23(1):31-8.